- FDA approves UCB drug for Parkinson's, restless legs syndrome
- Lyrica produces 'significant' improvement in restless legs syndrome
- Court upholds Lilly's patent for Cymbalta
- Horizant OKed as restless legs syndrome treatment
- UCB, Harvard enter research alliance focused on central nervous system, immunology
ATLANTA — UCB has launched a new drug for treating Parkinson's disease and restless legs syndrome, the company said Monday.
The Belgian drug maker announced the launch of Neupro (rotigotine) transdermal system, which the Food and Drug Administration approved in April. The drug is a once-daily patch that provides continuous delivery of rotigotine, a dopamine agonist, over 24 hours.
"The availability of Neupro is an important step forward for U.S. patients living with Parkinson's disease and restless legs syndrome," UCB CEO Roch Doliveux said. "UCB is dedicated to delivering innovative medicines like the Neupro transdermal patch to people living with serious illnesses, such as Parkinson's disease and restless legs syndrome, by combining the latest science and technology with our researchers' insights on the holistic needs of patients."